Physician profile
Sheena Sharma
NPI 1417099185
$3,497.40
in general payments reported to CMS, 2019-2025
24 companies · $627 in 2025
The $627 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $370 · 2020: $854 · 2021: $584 · 2022: $299 · 2023: $342 · 2024: $421 · 2025: $627.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,391.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,390.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $650.40 | 2019-2025 | Farxiga |
| Pfizer INC. | $465.15 | 2021-2025 | |
| Amgen INC. | $437.65 | 2019-2025 | Repatha, Otezla, Repatha |
| Janssen Pharmaceuticals, INC | $335.61 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $283.60 | 2019-2023 | |
| Amarin Pharma, INC. | $178.46 | 2020-2022 | |
| Alnylam Pharmaceuticals INC. | $175.97 | 2024-2025 | Onpattro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $162.00 | 2020-2025 | Jardiance |
| Inspire Medical Systems, INC. | $141.19 | 2024-2025 | Inspire |
| Lilly USA, LLC | $92.99 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $87.24 | 2024-2025 | Eliquis |
| Nestle Healthcare Nutrition INC. | $82.45 | 2023 | |
| Sanofi-Aventis U.S. LLC | $69.32 | 2019-2021 | |
| Novo Nordisk INC | $67.35 | 2020-2024 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $50.16 | 2024-2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $37.02 | 2023 | |
| Sumitomo Pharma America, INC. | $31.70 | 2024 | Gemtesa |
| Merck Sharp & Dohme LLC | $30.86 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $27.14 | 2020 | |
| Lexicon Pharmaceuticals, INC. | $21.19 | 2023 | Inpefa |
| Bardy Diagnostics, INC. | $20.00 | 2020 | |
| Medtronic, INC. | $19.23 | 2025 | Intellis Adaptivestim |
| Sanofi Pasteur INC. | $17.62 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheena Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.